

ITL Announces Positive Full Year Trading Update

ITL Health Group (“ITL”), an innovative global medical technology company, expects to announce very positive results for the financial year to 30 June 2017.

The second half results will show a significant improvement over the corresponding period in FY 2016 and follow the high growth achieved in the first half in which revenue grew 11% to \$17.5m, PBT increased 110% to \$2.12m and EBITDA rose 69% to \$2.7m.

Expected Full Year Results - Highlights:

- **Operating divisions have driven strong growth**
- **Revenue of \$35m (\$31.1m FY 2016)**
- **Profit Before Tax between \$3.5m to \$3.8m (\$0.3m FY 2016)**
- **EBITDA of \$5.0m (\$1.6m FY 2016)**
- **Successful targeting of \$3.3bn Blood Culture Testing market**
- **February posted highest monthly revenue and profit in ITL’s 23 year history**
- **\$4m spent on R&D (\$2m on MyHealthTest). \$3m of the \$4m has been expensed.**

The improved Full Year results have been driven by continued growth in the operating divisions, ITL Biomedical and ITL Healthcare.

Bill Mobbs, Executive Chairman commented: “The financial year has seen a step change for ITL. Our strategy to pursue high margin opportunities in emerging healthcare growth markets, and accelerate development of innovative patented products for the global healthcare markets has been a success.”

“We look forward to reporting positive Full Year results and the Board is looking to the remainder of 2017 and 2018 with confidence.”

Bill Mobbs
Executive Chairman

ITL Health Group

ITL is an innovative global medical technology company made up of four divisions; ITL BioMedical, ITL Healthcare, ITL Clinical & MyHealthTest.

ITL creates & manufactures leading edge medical devices for the clinical, blood banking, & laboratory markets & is a growing provider of specialist ancillary products for the blood culture testing market.

ITL holds an IP portfolio of 48 patents & sells into 55 countries.

MyHealthTest creates and markets highly innovative direct to consumer pathology testing for major chronic diseases.



Ranked 16th most Innovative Company by the AFR Innovative Companies Awards

Australian Securities Exchange
Code: ITD

Ordinary Shares
95,928,314

Board of Directors

Bill Mobbs	Executive Chairman
Mark Peatey Director	Non-executive
Andrew Turnbull Director	Non-executive
Trevor Doolan	Chief Financial Officer & Company Secretary

ITL Contact

Trevor Doolan Company Secretary
Phone: +61 3 8773 3050
Email: info@itl-limited.com

www.itl-limited.com

Media & Investors

Ben Knowles Walbrook IR
Phone: +61 426 277 760
Email: ben.knowles@walbrookir.com.au